摘要
目的:建立一种可以诊断肝癌的血清标志通量化筛选分析的抗体芯片技术.方法:以14种肝癌潜在标志物为研究对象并制备相应的抗体芯片,采用对血清样本进行生物素标记的抗体芯片分析策略,通过Wilcoxon非参数检验方法分析14种潜在蛋白标志物在44例肝癌患者和46名健康者的临床血清标本中的差异表达情况.结果:建立了针对生物素标记血清标本的抗体芯片分析技术,抗体芯片检测分析结果具有较好的重复性和准确性.HSP70、CK19、GPC3、PTMA、AFU、GP73、HBxAg、CA125等8种潜在标志的蛋白表达水平在44例肝癌与46例健康者血清中存在统计学差异(P<0.01).结论:本研究所建立的基于血清标本生物素标记的抗体芯片分析技术可以初步筛选出具有临床诊断价值的肝癌血清标志.
AIM：To develop an antibody microarray assay for screening serum biomarkers for liver cancer.METHODS：Antibody microarrays targeting 14 potential liver cancer biomarkers were prepared on aldehyde-coated glass slides.The prepared antibody microarrays were incubated with NHS-biotin-labeled serum samples and visualized with streptavidin-Cy3 fluorescent dye.The serum expression levels of 14 biomarkers were then compared between 44 liver cancer patients and 46 healthy individuals.RESULTS：The accuracy and reproducibility of data from the developed antibody microarray assay were satisfactory.The serum expression levels of HSP70,CK19,GPC3,PTMA,AFU,GP73,HBxAg and CA125 differed signifi cantly between liver cancer patients and healthy individuals（all P〈0.01）.CONCLUSION：An effective antibody microarray assay for screening serum biomarkers for liver cancer has been successfully developed.
出处
《世界华人消化杂志》
CAS
北大核心
2010年第31期3378-3383,共6页
World Chinese Journal of Digestology
基金
国家863高技术研究发展计划基金资助项目
No.2006AA02A311
No.2009AA043702
国家973重点基础研究发展计划基金资助项目
No.2006CB910803~~
关键词
抗体芯片
血清学标志
肝癌
Antibody microarray
Serum biomarker
Liver cancer
